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Abstract Accumulating evidence indicates that elevated ho-
mocysteine (Hcy) level occurs in first-episode schizophrenia
(FES) patients. We included 56 FES patients and 53 healthy
controls (HC). Plasma level of Hcy was significantly higher in
FES patients than HC (p=0.044). In addition, plasma levels of
high-density lipoproteins (HDL) and folate were significantly
lower in FES than in HC (p<0.001). Positive family
history of schizophrenia was associated with lower plasma
HDL (p=0.041) and vitamin B12 (p=0.017), as well as
higher level of Hcy (p=0.017). Patients with FES, who
abused cannabis, had higher levels of Hcy (p=0.017), as
well as lower levels of vitamin B12 (p=0.017) and HDL
(p=0.041). Plasma Hcy negatively correlated with duration
of untreated psychosis (r=−0.272, p=0.042). There was a
positive correlation between Hcy level and the severity of
negative symptoms (r=0.363, p=0.006) and general psy-
chopathology (r=0.349, p=0.008) assessed using Positive
and Negative Syndrome Scale (PANSS). Vitamin B12
level was negatively associated with the severity of nega-
tive symptoms (r=−0.406, p=0.002), while folate level
negatively correlated with general psychopathology score
(r=−0.365, p=0.006) in PANSS. These results indicate
that the severity of one-carbon metabolism alterations
and HDL deficiency might be associated with family
history of schizophrenia and cannabis abuse. Lower vitamin
B12 and folate along with elevated Hcy may influence the
severity of FES psychopathology.
Keywords One-carbonmetabolism . Homocysteine .
VitaminB12 . Folate . Cannabis . First-episode schizophrenia
Introduction
Re-methylation of homocysteine (Hcy) to methionine con-
stitutes one of the most important reactions catalysed in
one-carbon metabolism. There are numerous factors that
influence Hcy level including age, gender, cigarette
smoking, alcohol consumption, various medications and
polymorphisms in genes encoding enzymes acting in
one-carbon metabolism (Nygard et al. 1995; de Bree
et al. 2001; Dierkes et al. 2007). Two single nucleotide
polymorphisms (C677T and A1298C) in the methylenetet-
rahydrofolate (MTHFR) gene are also important genetic
predictors of Hcy level (Ulrich et al. 2002).
Hyperhomocysteinemia is widely recognized as the risk
factor for cardiovascular complications. Accumulating evi-
dence indicates that Hcy level is also increased in schizophre-
nia patients (Misiak et al. 2013). Inconsistent results indicate
that elevated Hcy level occurs in first-episode schizophrenia
(FES) patients. It has also been found that a 5-μmol/l increase
of plasma Hcy may increase the risk of schizophrenia by 70%
(Muntjewerff et al. 2006). Additionally, Hcy level may posi-
tively correlate with duration of untreated psychosis (DUP)
(Ayesa-Arriola et al. 2012), the severity of negative symptoms
(Goff et al. 2004; Petronijevic et al. 2008; Bouaziz et al. 2010)
and cognitive deficits (Levine et al. 2006). Some authors
suggest that mainly young schizophrenia males demonstrate
elevated Hcy levels (Levine et al. 2002). In the recent study by
Geller et al. (2013), it was found that siblings of schizophrenia
patients are also characterized by elevated Hcy level. These
findings are in line with previous studies showing the associ-
ation between polymorphisms in the MTHFR gene and
schizophrenia (Muntjewerff et al. 2006). Polymorphisms in
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the MTHFR gene might also predict the development of
metabolic side effects associated with second-generation an-
tipsychotics (Misiak et al. 2013). In addition, extensive evi-
dence indicates that the prevalence of lipid and glucose me-
tabolism disturbances is significantly higher in first-episode
and drug-naïve schizophrenia patients in comparison with
healthy controls (Chen et al. 2013; Wu et al. 2013; Cai et al.
2012; Spelman et al. 2007; Ryan et al. 2003; McEvoy et al.
2013). These findings point to the hypothesis that schizophre-
nia is in itself associated with metabolic deregulation.
A number of environmental factors including alcohol con-
sumption, cigarette smoking and various medications may
influence one-carbon metabolism (Nygard et al. 1995; de
Bree et al. 2001; Dierkes et al. 2007). There are also studies
showing low folate level due to cannabis abuse in pregnant
women (Knight et al. 1994) and undergraduate students
(Davis et al. 1978). However, the influence of cannabis on
plasma levels of Hcy, vitamin B12 and folate has not been
investigated so far. Cannabis abuse is increasingly recognized
as a risk factor for the development of psychotic disorders
including those from schizophrenia spectrum [for review see
(Casadio et al. 2011)]. In the register-based study of 18,478
Finnish inpatients with first hospitalization due to cannabis-
induced psychosis, the 8-year cumulative risk of schizophre-
nia spectrum diagnosis was estimated at 46 % (Niemi-Pynttari
et al. 2013). Notably, cannabis may exert long-term deleteri-
ous effects. For instance, the longitudinal study of 45,570
Swedish conscripts revealed that 31 % of cannabis users,
who later developed schizophrenia, stopped using cannabis
before the day of conscription (Zammit et al. 2002).
Several mechanisms may underlie the relationship between
Hcy and schizophrenia. It has been shown that Hcy adminis-
tered in high concentration is an agonist at the glutamate
binding site and a partial antagonist at the glycine co-agonist
site in NMDA receptors (Lipton et al. 1997). These findings
may be in line with studies showing that hypofunction of
glutamatergic transmission acts in the pathophysiology of
schizophrenia (Coyle et al. 2012). Furthermore, Hcy may
initiate neuronal apoptosis (Wang et al. 2012; Fujiki et al.
2012), trigger mitochondrial dysfunction (Kumar et al. 2011)
and promote oxidative stress (Dietrich-Muszalska et al. 2012).
Although there is considerable interest in one-carbon me-
tabolism alterations in schizophrenia, some questions still
remain. There is a scarcity of studies on first-episode and/or
drug-naïve schizophrenia patients (Garcia-Bueno et al. 2013;
Ayesa-Arriola et al. 2012; Kale et al. 2010; Bicikova et al.
2011). These studies have also provided contradictory results.
Therefore, it is still unresolved as to whether increased Hcy
level is associated with schizophrenia or occurs due to anti-
psychotic treatment. Furthermore, given the limited efficacy
of folate supplementation in the treatment of negative symp-
toms (Hill et al. 2011; Roffman et al. 2013b), it seems that
searching for clinical variables associated with Hcy level
alterations, which may predict the outcome of supplementa-
tion strategies, is warranted.
The aim of this study was to bridge the gaps in studies on
one-carbon metabolism in schizophrenia and explore whether
family history of schizophrenia and cannabis abuse influence
plasma levels of Hcy, vitamin B12 and folate in FES patients.
Material and methods
Subjects
We recruited 56 FES inpatients and 53 healthy controls (HC)
with negative family history of schizophrenia or other psy-
chotic disorders. Both groups were matched for age, gender,
body mass index (BMI) and ethnicity (all participants were
Caucasians). All subjects provided written informed consent
for participation in the study. Exclusion criteria were: mental
retardation and/or general brain disorder, supplementation of
folic acid or vitamins B, positive urine screening for illicit
drugs (cannabis, amphetamine, opiates and ecstasy), drug and/
or alcohol abuse/dependence during 1 year prior to the onset
of psychotic symptoms, severe somatic comorbidities, the use
of statins, fibrates, anti-hypertensive drugs or anti-diabetic
medications and inability to give informed consent. A diag-
nosis of schizophrenia was based on DSM-IV and ICD-10
criteria and confirmed using the Operational Criteria for
Psychotic Illness (OPCRIT) checklist. OPCRIT constitutes a
modern diagnostic tool creating a multidimensional insight
into the course and psychopathology of psychotic disorders
(McGuffin et al. 1991). Furthermore, OPCRIT has high reli-
ability determined using a kappa statistic in several classifica-
tion systems e.g. kappa for ICD-10 and DSM-III-R has been
estimated at 0.70 and 0.73 respectively (Williams et al. 1996).
We included the patients, who met DSM-IV and ICD-10
criteria for lifetime diagnosis of cannabis abuse, but who
reported cannabis cessation at least 1 year before the onset
of schizophrenia. In addition, psychopathology was examined
by using the Positive and Negative Syndrome Scale (PANSS)
(Kay et al. 1987). DUP was defined as the time from
appearance of the first prodromal symptoms to initiation
of antipsychotic treatment. Assessment of psychopathology
and diagnosing processes were based on structured inter-
views with the patients and on medical records. Clinical
assessment with OPCRIT checklist and PANSS was per-
formed by a trained and experienced clinician (B.M.).
Cigarette smoking was evaluated using pack-year index
and the Fagerström test (Pomerleau et al. 1989). Notably,
OPCRIT was completed for the lifetime course of the
disorder and evaluation of psychopathology with PANSS
was performed on the day of recruitment. All patients
were examined up to 16 days since the admission day.
Patients had aminimal dose of second-generation antipsychotics
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(olanzapine in 21 patients, risperidone in 21 patients and
amisulpride in 2 patients) on the day of assessment and there
were 12 drug-naïve patients. Agitation and hostility were man-
aged with haloperidol and benzodiazepines. No other psycho-
tropic medications were used. Average treatment duration was
5.10±4.45 days, while the average chlorpromazine equivalent
was 150±137.8 mg per day on the day of recruitment.
Metabolic parameters
Blood samples were obtained between 7.30 and 8.30 a.m.
after at least 10-h overnight fasting from the antecubital vein.
Plasma glucose, lipoproteins, vitamin B12, folate and total
cholesterol (TC) were determined using a Cobas 6000
analyzer (Roche, Switzerland). Enzymatic assay of hexo-
kinase was applied to measure plasma glucose. In addi-
tion, enzymatic assays of esterase and cholesterol oxidase
were used to measure TC level. High-density lipoprotein
(HDL) level was measured using polyethylene glycol-
modified enzymes. Similarly, enzymatic methods with
phosphoglycerol oxidase and peroxidase were used to
measure plasma triglycerides. Plasma low-density lipopro-
teins (LDL) were calculated using the Friedewald equation
(Friedewald et al. 1972): LDL (mg/dl) = TC – (HDL + TG/5).
Plasma Hcy level was measured using a chemiluminescence
method in an Immulite 2000 analyzer (Siemens, Germany). In
addition, elektrochemiluminescence method was used to mea-
sure plasma folate and vitamin B12.
Weight and height were determined using a balance beam
scale with stadiometer, which was located on a firm and
horizontal surface. All subjects wore light clothing and stood
straight without shoes. Body mass index (BMI) was calculat-
ed by dividing body mass in kilograms by the square of the
height in meters (kg/m2).
Statistics
Demographic and clinical data between FES patients and HC,
between patients with positive and negative history of schizo-
phrenia, as well as between patients with and without lifetime
diagnosis of cannabis abuse were compared using the Mann–
Whitney U-test (age, DUP, BMI, biochemical parameters,
pack-year index, Fagerström test score, treatment duration,
chlopromazine equivalent, PANSS subscales) and χ2 test
(gender, the number of cigarette smokers). Differences were
considered as statistically significant if the p value was <0.05.
Correlations between biochemical parameters and illness du-
ration, age of onset of cannabis use, pack-year index and
Fagerström test score were assessed using the Spearman’s
rank correlation coefficient. Partial Bonferroni correction
(Gong et al. 2000), which takes into account correlations
between studied variables, was applied to the level of signif-
icance due to multiple comparisons of several metabolic
parameters that are not independent. Multivariable linear re-
gression model was performed to determine the independent
predictors of Hcy level in FES patients. The model included:
age, gender, BMI, pack-year index, CPZ equivalent, treatment
duration, as well as plasma levels of folate, vitamin B12, LDL,
HDL, TG and TC. All analyses were performed using the
Statistical Package for Social Sciences (SPSS) version 20.
Results
The comparison of FES patients and healthy controls (HC) is
presented in Table 1. Mean Hcy level was significantly higher
(p=0.044) in FES patients (12.38±5.76 μmol/l) in compari-
son with HC (11.42±6.97 μmol/l). In addition, mean folate
and HDL levels were significantly lower (p<0.001) in FES
patients (6.32±2.85 ng/ml and 51.62±16.19 mg/dl, respec-
tively) in comparison with HC (11.10±15.20 ng/ml and
66.07±17.46 mg/dl, respectively). These differences cannot
be attributed to differences in age, gender and BMI.
Notably, mean pack-year index and the Fagerström test score
were significantly higher (p=0.038 and p=0.022, respectively)
in FES patients (2.09±3.66 and 1.91±2.79, respectively) in
comparisonwith HC (1.01±2.40 and 0.83±1.79, respectively).
However, there was no correlation between biochemical







Age (years) 27.19±7.30 25.68±2.89 0.869
Gender (males/females) 30/26 26/27 0.703
BMI (kg/m2) 23.62±3.92 22.40±2.95 0.178
Glucose (mg/dl) 85.72±9.43 86.74±10.83 0.121
LDL (mg/dl) 93.16±31.81 85.68±24.65 0.317
HDL (mg/dl) 51.62±16.19 66.07±17.46 <0.001†
TC (mg/dl) 168.21±37.63 170.81±30.89 0.727
TG (mg/dl) 112.67±61.25 95.11±45.42 0.123
Hcy (μmol/l) 12.38±5.76 11.42±6.97 0.044
Folate (ng/ml) 6.32±2.85 11.10±15.20 <0.001†
Vitamin B12 (pg/ml) 399.21±202.47 388.72±146.78 0.671
The number of cigarette
smokers
21 10 0.036
Pack-year index 2.09±3.66 1.01±2.40 0.038
Fagerström test 1.91±2.79 0.83±1.79 0.022
Abbreviations: BMI body mass index, FES first-episode schizophrenia,
HC healthy controls, Hcy homocysteine, HDL high density lipoproteins,
LDL low density lipoproteins, TC total cholesterol, TG triglycerides
* p-value refers to the comparison ofmean-ranks using theMann–Whitney
U-test. Significant differences (p<0.05) were marked in bold
† Significant differences after application of partial Bonferroni correction
(p<0.0058)
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parameters and the indices of cigarette smoking (Table 2).
Similarly, treatment duration and chlorpromazine equivalent
did not correlate with biochemical parameters (Table 2). There
were no significant gender differences in Hcy, folate and
vitamin B12 levels neither in FES patients nor in HC (data
not shown). The linear regression model revealed that after
controlling for confounding variables, Hcy levels in FES pa-
tients were associated only with folate levels (B=−1.10,
95CI% −1.65 to −0.56, p<0.0001).
Table 3 presents a comparison of FES patients with and
without positive family history of schizophrenia. Patients with
a positive family history of schizophrenia in first and/or sec-
ond degree relatives had significantly higher mean levels of
Hcy in comparison with those with a negative family history
of schizophrenia (13.40±6.35 μmol/l vs. 9.86±2.74 μmol/l,
p=0.017). In addition, mean plasma levels of HDL and vita-
min B12 were significantly lower in FES subjects (p=0.041
and p=0.017, respectively), who had first and/or second
degree relatives with schizophrenia (49.04±15.60 mg/dl
and 350.24±142.98 pg/ml, respectively) in comparison
with those, who did not have (58.10±16.28 mg/dl and
521.64±273.45 pg/ml, respectively). There were no between
group differences with respect to family history of schizophrenia
in age, gender, BMI, psychopathological manifestation assessed
by PANSS, the Fagerström test score and pack-year index.
We divided FES patients into two subgroups—those with a
lifetime diagnosis of cannabis abuse and those, who had never
abused cannabis. Patients with a lifetime diagnosis of cannabis
Table 2 Correlation coefficients for confounders associated with antipsychotic treatment and cigarette smoking (p>0.05)
FES patients HC
Pack-year index Fagerström score Chlorpromazine equivalent Treatment duration Pack-year index Fagerström score
Glucose r=−0.070 r=−0.078 r=−0.058 r=−0.048 r=0.025 r=0.023
LDL r=0.195 r=0.145 r=0.122 r=−0.034 r=0.243 r=0.237
HDL r=−0.090 r=−0.101 r=−0.143 r=−0.100 r=−0.007 r=−0.010
TC r=0.180 r=0.125 r=0.023 r=−0.094 r=0.184 r=0.186
TG r=0.004 r=−0.016 r=0.045 r=−0.164 r=0.094 r=0.105
Hcy r=0.058 r=0.062 r=−0.049 r=−0.136 r=0.037 r=0.040
Folate r=−0.134 r=−0.168 r=−0.045 r=0.099 r=0.065 r=0.073
Vitamin B12 r=0.006 r=0.028 r=0.064 r=0.189 r=−0.083 r=−0.062
Abbreviations: BMI body mass index, FES first-episode schizophrenia, HC healthy controls, Hcy homocysteine, HDL high density lipoproteins,
HyperHcy hyperhomocysteinemia, LDL low density lipoproteins, TC total cholesterol, TG triglycerides
Table 3 The comparison of first-
episode schizophrenia patients
with respect to family history of
schizophrenia
Abbreviations: BMI body mass
index, Hcy homocysteine, HDL
high density lipoproteins, LDL
low density lipoproteins, PANSS
the Positive and Negative Syn-
drome Scale, TC total cholesterol,
TG triglycerides
* p-value refers to the comparison
of mean-ranks using the Mann–
Whitney U-test. Significant differ-
ences (p<0.05) were marked in
bold. There was no significant dif-









Age (years) 26.07±6.68 30.00±8.23 0.102
Gender (males/females) 7/9 23/17 0.388
BMI (kg/m2) 24.16±3.95 22.29±3.66 0.091
Glucose (mg/dl) 86.10±9.39 84.76±9.77 0.599
LDL (mg/dl) 94.85±32.43 88.93±30.76 0.479
HDL (mg/dl) 49.04±15.60 58.10±16.28 0.041
TC (mg/dl) 168.43±39.21 167.69±34.56 0.913
TG (mg/dl) 116.23±62.25 103.75±59.69 0.272
Hcy (μmol/l) 13.40±6.35 9.86±2.74 0.017
Folate (ng/ml) 6.17±2.89 6.68±2.81 0.425
Vitamin B12 (pg/ml) 350.24±142.98 521.64±273.45 0.017
The number of cigarette smokers 5 16 0.761
Pack-year index 1.93±3.11 2.46±4.87 0.746
Fagerström test 2.00±2.76 1.68±2.93 0.678
PANSS—positive symptoms score 23.50±3.29 23.47±5.97 0.793
PANSS—negative symptoms score 18.00±7.73 17.67±7.38 0.806
PANSS—general psychopathology score 41.00±6.78 43.22±8.05 0.342
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abuse had significantly lower mean levels of plasma HDL
(45.83±18.56 mg/dl vs. 55.10±18.56, p=0.041) and vitamin
B12 (382.48±134.25 pg/ml vs. 409.25±235.44, p=0.017) in
comparison with those, who had not abused cannabis
(Table 4). On the other hand, lifetime diagnosis of cannabis
abuse was associated with significantly higher mean level
of plasma Hcy (14.85±7.35 μmol/l vs. 10.91±3.99 μmol/l,
p=0.017). However, age at onset of cannabis use was not
associated with alterations in plasma Hcy, folate and vitamin
B12 (Table 5). Notably, lifetime diagnosis of cannabis abuse
was not associated with BMI, psychopathological manifesta-
tion assessed by PANSS and the indices of cigarette smoking.
However, there were significantly more males among FES
patients with a lifetime diagnosis of cannabis abuse in com-
parison with the group of patients, who had never abused
cannabis (90.47 vs. 31.42 %, p<0.001).
Finally, we tested the hypothesis as to whether DUP and
psychopathological manifestation of FES patients are associ-
ated with plasma levels of Hcy, folate and vitamin B12
(Table 5). We found that Hcy level predicted shorter DUP
(r=−0.272, p=0.042). Furthermore, Hcy level positively cor-
related with the severity of negative symptoms and general
psychopathology assessed by PANSS (r=0.363, p=0.006 and
r=0.349, p=0.008, respectively). In addition, plasma levels of
vitamin B12 and folate negatively correlated with the severity
of negative symptoms (r=−0.406, p=0.002) and general psy-
chopathology (r=−0.365, p=0.006) in PANSS, respectively.
Differences in HDL and folate levels between FES patients
and HC, as well as gender differences between FES patients
with and without lifetime diagnosis of cannabis abuse
remained significant after application of partial Bonferroni
correction (Tables 1 and 4).
Table 4 The comparison of first-
episode schizophrenia patients
with respect to lifetime diagnosis
of cannabis abuse
Abbreviations: BMI body mass
index, Hcy homocysteine, HDL
high density lipoproteins, LDL
low density lipoproteins, PANSS
the Positive and Negative Syn-
drome Scale, TC total cholesterol,
TG triglycerides
* p-value refers to the comparison
of mean-ranks using the Mann–
Whitney U-test
†Significant differences after ap-
plication of partial Bonferroni cor-
rection (p<0.0054). Significant









Age (years) 23.81±7.94 29.22±4.50 0.102
Gender (males/females) 19/2 11/24 <0.001†
BMI (kg/m2) 23.98±3.24 23.41±4.39 0.091
Glucose (mg/dl) 85.11±8.85 86.08±9.87 0.599
LDL (mg/dl) 88.08±35.09 96.21±29.77 0.479
HDL (mg/dl) 45.83±18.56 55.10±18.56 0.041
TC (mg/dl) 160.23±47.31 173.00±30.19 0.913
TG (mg/dl) 116.95±73.87 110.09±53.31 0.272
Hcy (μmol/l) 14.85±7.35 10.91±3.99 0.017
Folate (ng/ml) 5.14±1.88 7.02±3.12 0.425
Vitamin B12 (pg/ml) 382.48±134.25 409.25±235.44 0.017
The number of cigarette smokers 11 10 0.093
Pack-year index 2.26±3.09 1.98±4.00 0.746
Fagerström test 2.52±2.87 1.54±2.71 0.678
PANSS—positive symptoms score 25.09±6.23 22.51±4.50 0.101
PANSS—negative symptoms score 17.23±7.75 18.08±7.30 0.511
PANSS—general psychopathology score 43.85±7.55 41.82±7.81 0.265
Table 5 Correlations between plasma homocysteine, vitamin B12 and folate and selected clinical variables
Homocysteine (μmol/l) Vitamin B12 (pg/ml) Folate (ng/ml)
DUP (days) r=−0.272, p=0.042 r=−0.068, p=0.617 r=0.168, p=0.217
Age at onset of cannabis use (years) r=0.291, p=0.242 r=−0.408, p=0.093 r=−0.007, p=0.977
PANSS—positive symptoms score r=0.093, p=0.494 r=0.031, p=0.818 r=−0.222, p=0.100
PANSS—negative symptoms score r=0.363, p=0.006 r=−0.406, p=0.002 r=−0.111, p=0.415
PANSS—general psychopathology score r=0.349, p=0.008 r=0.013, p=0.922 r=−0.365, p=0.006
Abbreviations: DUP duration of untreated psychosis, PANSS Positive and Negative Syndrome Scale
Significant differences (p<0.05) were marked in bold
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Discussion
In this study, we have found that FES patients are charac-
terized by higher plasma Hcy and lower levels of folate
and HDL. These results cannot be attributed to differences
in age, gender, BMI, cigarette smoking or antipsychotic
treatments. Our findings are in agreement with previous
studies showing higher levels of Hcy and lower levels of
folate or vitamin B12 in first-episode psychosis patients
(Garcia-Bueno et al. 2013; Ayesa-Arriola et al. 2012;
Kale et al. 2010). Significantly lower levels of HDL are
also in line with previous studies on FES patients (Wu
et al. 2013; Phutane et al. 2011; Fleischhacker et al. 2013).
Interestingly, in the European First-Episode Schizophrenia
Trial (EUFEST), suboptimal HDL level was present in
28.5 % patients and was the most prevalent baseline
metabolic risk factor (Fleischhacker et al. 2013).
Most interestingly, we have found that positive family
history of schizophrenia in first and/or second degree relatives
is associated with higher plasma Hcy, as well as with lower
levels of HDL and vitamin B12. However, these results
should be interpreted with caution as they were not significant
after application of partial Bonferroni correction. This associ-
ation has not been reported so far. The recent study by Geller
et al. (2013) provided that siblings of patients with schizo-
phrenia have higher Hcy levels than healthy controls.
Simultaneously, there was no difference in Hcy level between
schizophrenia patients and their siblings. Furthermore, there
are studies showing that type 2 diabetes and obesity are more
common in relatives of patients with schizophrenia
(Mukherjee et al. 1989; Martins et al. 2001) or non-affective
psychosis (Fernandez-Egea et al. 2008). These findings, along
with those presented in this article, suggest that schizophrenia
is in itself associated with metabolic dysregulation that orig-
inates from genetic susceptibility. On the basis of a meta-
analysis, Muntjewerff (Muntjewerff et al. 2006) provided
evidence that the C677T polymorphism in the MTHFR gene
increases the risk of schizophrenia. Furthermore, there are
studies showing that the C677T polymorphism in the
MTHFR gene is associated with an earlier age of schizophre-
nia onset (El-Hadidy et al. 2013; Vares et al. 2010); however,
some authors have not confirmed this finding (Saetre et al.
2011, 2012; Peerbooms et al. 2010). Finally, this polymor-
phism has been found to influence the development of meta-
bolic syndrome components in response to antipsychotic treat-
ment (Srisawat et al. 2013; Ellingrod et al. 2008, 2012; van
Winkel et al. 2010a, b), cognitive performance (Kontis et al.
2013; Roffman et al. 2008a, b, 2011b), grey matter density
(Zhang et al. 2013) and the activation of dorsal anterior
cingulate cortex (Roffman et al. 2011a), the severity of
aggressive behaviours (Dong et al. 2012) and negative
symptoms (Roffman et al. 2008c, 2013a), as well as the
efficacy of folate supplementation in the treatment of
negative symptoms (Hill et al. 2011; Roffman et al. 2013b)
in schizophrenia patients.
We have also found that more severe negative symptoms
are associated with higher Hcy and lower vitamin B12 levels.
These results are in line with previous studies showing
that higher Hcy and lower folate levels are associated with
higher severity of negative symptoms (Goff et al. 2004;
Petronijevic et al. 2008; Bouaziz et al. 2010). However,
there are also studies, which have failed to confirm this
relationship (Neeman et al. 2005; Ma et al. 2009; Ayesa-
Arriola et al. 2012). Inconsistent results might be due to
recruitment of various subgroups of patients including
first-episode schizophrenia-spectrum patients, acutely re-
lapsed inpatients or chronic subjects. Notably, we have
also found that higher Hcy and lower folate levels may
predict more general psychopathology symptoms as
assessed with the PANSS. These findings, along with the
association with negative symptoms, have not been reported
in FES patients so far. It should be noted that our results
indicate an inverse relationship between plasma Hcy and
DUP. The majority of previous studies have not confirmed
this association (Petronijevic et al. 2008; Ma et al. 2009;
Mabrouk et al. 2011). However, Ayesa-Arriola et al. (2012)
found that higher Hcy levels may predict a shorter duration of
untreated psychosis (DUP) in patients with first-episode
schizophrenia-spectrum disorders. The exact mechanism of
this association remains unknown as there is a scarcity of
studies investigating the influence of antipsychotic treatment
on Hcy level (Bicikova et al. 2011; Eren et al. 2010;
Wysokinski and Kloszewska 2013). Moreover, these studies
have provided contradictory results (Bicikova et al. 2011;
Eren et al. 2010; Wysokinski and Kloszewska 2013). It might
be hypothesized that a negative correlation between Hcy
levels and DUP originates frommore severe psychopathology
in patients with higher Hcy levels since we have shown that
Hcy level positively correlates with the severity of negative
symptoms and general psychopathology assessed by PANSS.
Therefore, more severe psychopathology due to high Hcy
levels may shorten DUP.
We have also shown that a lifetime diagnosis of cannabis
abuse is associated with higher Hcy, as well as lower HDL and
vitamin B12 levels in FES patients. Notably, these differences
were not significant after application of partial Bonferroni
correction. We excluded current cannabis users with FES in
order to increase the reliability of schizophrenia diagnosis.
Notably, these results should be interpreted with caution, as
we did not assess cannabis use in healthy controls.
Furthermore, it might be feasible to examine one-carbon
metabolism alterations in first-episode psychosis patients,
who currently use cannabis. In the light of current knowledge,
it is hard to indicate a putative linkage between cannabis use
and Hcy metabolism. There are studies showing the associa-
tion between cannabis use and low folate levels in pregnant
666 Metab Brain Dis (2014) 29:661–670
women (Knight et al. 1994) and undergraduate students
(Davis et al. 1978). These authors suggested that low folate
level occurs most likely due to nutritional constraint. There are
also studies showing that cannabinoids may impair the uptake
of folate into BeWo cells (Araujo et al. 2009) and human
syncytiotrophoblasts (Keating et al. 2009). However, the exact
mechanism of this interaction remains unclear and requires
further investigation.
Notably, our study has some limitations that may influence
the results. These include sample size, the lack of quantitative
assessment of cannabis use and evaluation of dietary intake,
possible under-reporting bias of cannabis use within 1 year
prior to the onset of psychosis and the influence of antipsy-
chotic treatment. Although our sample was not large, it cor-
responds with sample sizes of previous studies on one-carbon
metabolism deregulation in drug-naïve and/or FES patients
(Bicikova et al. 2011; Kale et al. 2010; Bouaziz et al. 2010).
Rates of under-reported illicit drug use in schizophrenia pa-
tients are considerable. For instance, in the recent study by
Bahorik et al. (2013), more than half of patients did not report
using illicit drugs. It is noteworthy that under-reporting bias
seems to be undetectable in studies on lifetime use of illicit
drugs. It cannot be ruled out that our results are confounded by
the lack of evaluation of dietary intake. However, all subjects
had BMI, folate and vitamin B12 levels within the normal
range. Finally, we cannot exclude that our results are influ-
enced by the use of antipsychotics. There is no doubt that
antipsychotic treatment is strongly associated with the devel-
opment of metabolic syndrome in schizophrenia (Hasnain
et al. 2010). However, neither treatment duration nor chlor-
promazine equivalent significantly influenced our results.
Additionally, the observational study of drug-naïve schizo-
phrenia patients by Bicikova et al. (2011) did not reveal
significant changes in Hcy level after a 6-month follow-up.
Similarly, the cross-sectional study by Wysokinski and
Kloszewska (2013) did not reveal the influence of clozapine
on Hcy level. There is only one study (Eren et al. 2010) on
chronic schizophrenia patients showing that higher doses of
typical antipsychotics (CPZ equivalent>400 mg) might be
associated with lower levels of plasma folate, but not Hcy or
vitamin B12.
In conclusion, it should be noted that metabolic alterations
seem to bemore common in FES patients. It is most likely that
schizophrenia is in itself linked to metabolic disturbances that
have strong genetic underpinnings. Alterations in one-carbon
metabolism seem to be associated with FES psychopathology.
An important but preliminary finding from our study, is the
long-term deleterious effect of cannabis use on metabolic
profile. The influence of various clinical factors on the
severity of one-carbon metabolism dysfunction warrant the
need of a personalized medicine approach in the treatment
of psychopathological symptoms of schizophrenia and co-
morbid early deleterious alterations in metabolic profile.
The results of our study could provide additional support
to the ‘chicken–egg dilemma’ with respect to metabolic
alterations in schizophrenia. The majority of studies focus
on the fact that antipsychotic treatment increases the risk
of metabolic disturbances in the course of schizophrenia;
however, it should be stressed that there are also metabolic
alterations that occur prior to the onset of psychosis and
that are more common among patients having relatives
with schizophrenia. Such observations should lead to fur-
ther research projects looking more closely into bidirec-
tional relationships between biochemical metabolic markers
and schizophrenia.
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